Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Solitomab

Known as: Anti-EpCAM BiTE 
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Bispecific

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct… Expand
Is this relevant?
Review
2017
Review
2017
Recent advances of bispecific antibodies in solid tumors
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
BACKGROUND Uterine serous carcinoma is an aggressive form of endometrial cancer that carries an extremely poor prognosis… Expand
Is this relevant?
Review
2016
Review
2016
Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Bispecific T-cell engager (BiTE(®)) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor… Expand
Is this relevant?
2015
2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
BackgroundUterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex…
BACKGROUND Solitomab is a novel, bispecific, single-chain antibody that targets epithelial cell adhesion molecule (EpCAM) on… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice
 
Is this relevant?
2014
2014
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE